thalidomide has been researched along with Bright Disease in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In comparison with untreated mice, mice treated with 10 mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10 mg/kg of thalidomide plus PL or MMF plus PL." | 3.78 | Attenuation of nephritis in lupus-prone mice by thalidomide. ( Choi, KH; Kim, BS; Lee, SK; Lee, SW; Park, KH; Park, YB; Yang, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vertolli, U | 1 |
| Berno, T | 1 |
| Riva, M | 1 |
| Adami, F | 1 |
| Angelini, A | 1 |
| Calò, LA | 1 |
| Lee, SW | 1 |
| Park, YB | 1 |
| Yang, J | 1 |
| Park, KH | 1 |
| Lee, SK | 1 |
| Choi, KH | 1 |
| Kim, BS | 1 |
| Ramadan, KM | 1 |
| McKenna, KE | 1 |
| Morris, TC | 1 |
3 other studies available for thalidomide and Bright Disease
| Article | Year |
|---|---|
A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Fema | 2018 |
Attenuation of nephritis in lupus-prone mice by thalidomide.
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; DNA; Dose-Response Relationship, Drug; | 2012 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2006 |